Back to search results

Observational Study of Cardiovascular Magnetic Resonance Imaging

This study aims to improve how doctors diagnose and manage heart problems using a special type of imaging called cardiovascular magnetic resonance imaging (MRI). Researchers are developing and testing new ways to image the heart and blood vessels with MRI. They want to see if these new imaging methods, called "novel pulse sequences," work well in both people with heart conditions and healthy volunteers. To join, you must be 18 years or older and either be having a clinically indicated MRI of your heart or blood vessels, or be a healthy volunteer. The main goal is to see how many people get good quality images from these new MRI methods. The study is currently recruiting up to 3400 participants.

Study design
This is an observational study that plans to enroll up to 3400 participants. It is not specified if it is randomized or blinded.
What's involved
You will have a medical history screening, a physical exam, blood tests, and an electrocardiogram (ECG). You will then have your scheduled MRI scan.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for evaluating the performance of novel pulse sequences is measured at 1 day.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04927429

Technical Development of Cardiovascular Magnetic Resonance Imaging

Recruiting
Not specifiedAges 18+Observational
National Heart, Lung, and Blood Institute (NHLBI)
~3,400 participants
Updated 2026-07-30 on ClinicalTrials.gov

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To evaluate performance of novel pulse sequences for cardiovascular MRI in patients and healthy volunteers of both genders
Measured over 1 day

Conditions

Cardiovascular Disease

Explore related trials

CardiomyopathyCardiovascular DisorderCongenital Heart DiseaseCoronary Artery DiseaseHeart Failure

Where it's being run

2 sites across 2 states
District of Columbia1
Maryland1

Study leadership

  • Eric E Morgan, M.D. · PRINCIPAL_INVESTIGATOR · National Heart, Lung, and Blood Institute (NHLBI)

Who to contact

Stacian D Awojoodu, C.R.N.P.
[email protected]
(240) 408-0498
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Provision of signed and dated informed consent form by subject
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, 18 years or older
Subjects undergoing a clinically indicated MRI examination. Examples of medical indications include known or suspected heart failure or cardiomyopathy, chest pain with known or suspected coronary artery disease, unexplained dyspnea, valve disease, known or suspected congenital heart disease, cardiac masses and known or suspected aortic disease, exposure to cardiotoxic drugs, and systemic illnesses with known associated cardiovascular involvement.
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, 18 years or older

Exclusion

Unable to undergo magnetic resonance imaging because of:
Central nervous system aneurysm clips
Implanted neural stimulator
Implanted cardiac pacemaker or defibrillator
Cochlear implant
Ocular foreign body (e.g. metal shavings)
Implanted Insulin pump
Metal shrapnel or bullet
2.For examinations that include contrast injection of GBCA:
Bronchospastic lung disease with ongoing wheezing or history of significant reactive airway disease
Second- or third- degree atrioventricular blood, sinus node disease without a functioning MR conditional pacemaker
Systolic blood pressure \< 90 mmHg
Uncontrolled hypertension (systolic BP \> 200 mmHg or diastolic BP \> 110 mmHg)
Recent (\< 48hr) use of dipyridamole of dipyridamole- containing medications
Known hypersensitivity to adenosine or regadenoson.
Unstable angina, acute coronary syndrome, or less than 2- 4 days after an acute myocardial infarction
For regadenoson only: seizure disorder as regadenoson may lower seizure threshold. Aminophylline should not be used in cases of seizures associated with Regadenoson.
Pregnant Women.
Lactating Women for administration of GBCA unless the subjects is willing to discard the milk for 24 hours after receiving gadolinium
Known history of major illness, including, but not limited to having a hypertension diagnosis in need of anti-hypertensive medication, myocardial infarction, diabetes, familial hypercholesterolemia, cardiomyopathy, congenital heart disease, moderate or severe valvular disease, cerebrovascular insult or peripheral vascular disease, symptoms of angina or dyspnea, current smoker.
Decisionally impaired individuals

What this trial measures

  • To evaluate performance of novel pulse sequences for cardiovascular MRI in patients and healthy volunteers of both genders1 day

    Clinical performance of pulse sequences measured as the number of subjects with custom and novel pulse sequences that has provided diagnostic quality image